Trials / Terminated
TerminatedNCT06824870
Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis
Exploratory Study Evaluating the Effects of RV5026B Dermo-cosmetic Treatment ET1732 Formula Applied for 2 Months in Adult Subjects With Erythrocouperosis Associated With Pityriasis Folliculorum.
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Pierre Fabre Dermo Cosmetique · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This exploratory study aims to evaluate the effects of the test product RV5026B - ET1732 on erythema, as well as on the sensations of discomfort and relief perceived in subjects with erythrocouperose and associated pityriasis folliculorum. We wish to evaluate: * firstly the test product alone in order to quantify the effects on the signs \& symptoms on the entire face, * then the contribution of the test product in addition to a reference topical treatment. The test product RV5026B - ET1732 was developed to: * Reduce redness, even if it has already set in, and help limit its reappearance * Soothe the sensations of heating and discomfort associated
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | RV5026B - ET1732 - Period 1 | Period 1 (1 month): The tested product RV5026B - ET1732 will be applied twice a-day on full-face The product sould be applied in sufficient quantity to cover the application area. |
| DRUG | reference topical product - Period 2 | Period 2 (1 month) : the reference topical product, prescribed by the investigator will applied each evening on the whole face. |
| OTHER | RV5026B - ET1732 - Period 2 | Period 2 (1 month) : The tested product RV5026B - ET1732 will be applied twice a-day on randomised half-face. The evening application will be done 15 minutes after the application of the reference treatment. Hands must be washed between the application of the 2 products. |
Timeline
- Start date
- 2023-10-20
- Primary completion
- 2025-02-20
- Completion
- 2025-02-20
- First posted
- 2025-02-13
- Last updated
- 2025-04-08
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06824870. Inclusion in this directory is not an endorsement.